arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Stoke Therapeutics, Inc.

STOK
$26.08 ▼ -1.35 (-4.90%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
36 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Stoke Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.8B
Dividend Yield —
Revenue Growth 5.9% ↗
Op. Margin None
ROIC -21.9% ↘
FCF / Share $-0.96 ↘
Trailing P/E —
Price / Book 4.8x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

36-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$11.26M
↑ +5.9% —
Net Income Profit after all expenses
$-50.00M
— 0.0% —
Operating Margin Operating profit as % of sales
-405.3%
↓ -105.1% 14th
FCF / Share Free cash flow per share
$-0.96
↓ -84.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
42
Returns ↑
42
Financial Health →
3
Cash Quality
2

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 9 years · 36 quarters